{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Garber HR"],"pubmed_abstract":["A clinical trial was conducted to assess the feasibility of enrolling patients with Stage II or III hormone receptor positive (HR+)/HER2-negative breast cancer to pre-operative dual PD-L1/CTLA-4 checkpoint inhibition administered prior to neoadjuvant chemotherapy (NACT). Eight eligible patients were treated with upfront durvalumab and tremelimumab for two cycles. Patients then received NACT prior to breast surgery. Seven patients had baseline and interval breast ultrasounds after combination immunotherapy and the responses were mixed: 3/7 patients experienced a ≥30% decrease in tumor volume, 3/7 a ≥30% increase, and 1 patient had stable disease. At the time of breast surgery, 1/8 patients had a pathologic complete response (pCR). The trial was stopped early after 3 of 8 patients experience"],"journal":["Oncotarget"],"pagination":["238-247"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10950364"],"repository":["biostudies-literature"],"pubmed_title":["Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer."],"pmcid":["PMC10950364"],"pubmed_authors":["Raghavendra AS","Garber HR","Sharma P","He Z","Mittendorf EA","Litton JK","Santiago L","Basu S","Jindal S","Chu K","Yam C","Adrada BE"],"additional_accession":[]},"is_claimable":false,"name":"Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer.","description":"A clinical trial was conducted to assess the feasibility of enrolling patients with Stage II or III hormone receptor positive (HR+)/HER2-negative breast cancer to pre-operative dual PD-L1/CTLA-4 checkpoint inhibition administered prior to neoadjuvant chemotherapy (NACT). Eight eligible patients were treated with upfront durvalumab and tremelimumab for two cycles. Patients then received NACT prior to breast surgery. Seven patients had baseline and interval breast ultrasounds after combination immunotherapy and the responses were mixed: 3/7 patients experienced a ≥30% decrease in tumor volume, 3/7 a ≥30% increase, and 1 patient had stable disease. At the time of breast surgery, 1/8 patients had a pathologic complete response (pCR). The trial was stopped early after 3 of 8 patients experience","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-07-14T18:15:42.769Z","creation":"2025-04-05T17:30:28.386Z"},"accession":"S-EPMC10950364","cross_references":{"pubmed":["38502947"],"doi":["10.18632/oncotarget.28567"]}}